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CHAPTER I 
INTRODUCTION 
Among the first reports involving serum protein binding of drugs 
is one covering work done by Moore and Roaf {1904). They demonstrated 
that several volatile compounds, such as ether and chloroform, had a 
greater solubility in serum than in saline. This was attributed to 
"substance interaction with proteins". Historically, a significant 
advance in the era of modern drug-protein interaction was contributed 
by Davis (1942, 1943). His research related the binding of sulfonamides 
by plasma proteins to drug distribution in body fluids and indicated that 
the bound portions were bacteriostatically inactive. Within eight years, 
several investigations describing serum-drug interaction of sulfonamide, 
digitoxin, organic ions, penicillin, inorganic ions, and serum albumin 
binding sites were published {Derouax, 1943; Farwaz and Farah, 1944; . 
Klotz and Walker, 1947; Eagle, 1947; Scatchard, 1949, 1950; and Karush, 
1949 1 1950) • 
A classic review by Goldstein (1949) regarding drug and plasma 
protein interactions focused upon the consequences of drug binding on 
half-life, efficacy, distribution, and excretion of drugs. His statement 
that "the capacity of drug molecules to enter into specific combinations 
with proteins poses for pharmacology its most :f'undamental task - to 
comprehend the intimate nature of drug action in terms of these molecular 
interactions" summarizes the importance of drug-plasma protein inter-
actions. 
1. 
The Goldstein publication contributed to an increased awareness 
and stimulated many researchers to investigate the protein drug binding 
phenomenon. Since 1949, many publications describing the binding of a 
variety of drugs by plasma proteins have appeared. Among the drug exam-
ined were anticoagulants, hypnotics, parasympatholytics, anti-infectives, 
CNS stimulants, cardiovascular agents, etc. (Meyer and Guttman, 1968). 
Weiner et al (1950) showed that several human protein fractions 
had different affinities for binding dicumarol. They found that beta and 
gamma globulins bound 20% of the drug while alpha globulin and albumin 
bound 50 and 99% respectively. The low free plasma level, slow rate of 
metabolism, slow rate of transformation, and low elimination rate of 
dicumarol were attributed to extensive plasma protein binding. 
Mark et al (1951) found that procaine amide was primarily 
localized in various tissues, i.e. kidney, liver, spleen, etc. To esti-
mate the extent of drug localization, it was necessary to determine the 
amount of procaine amide bound by plasma proteins. They found that 15% 
of the drug was bound to non-diffusible constituents of plasma. 
A report by Tonnesen (1956) stated that the slow elimination 
of atropine in man might be due to interaction with plasma protein. Em-
ploying ultrafiltration and ultracentrifugation techniques, he found that 
a~er the administration of a therapeutic dose of atropine, 50% was ab-
sorbed onto the plasma proteins. Tonnesen concluded that the plasma 
proteins served as a carrier by which atropine is transported to various 
organs. He also intimated that this binding may slow the elimination of 
atropine in man .• 
2. 
In vivo results reported by Paul et al (1960) showed that 30% 
of the non-ionized nitro:fUrans (nitro:fUrazone) were bound to plasma pro-
teins, 50 - 90% of the anionic compounds (nitrofuran), while the cationic 
drugs (furaltadone) were not bound to any appreciable extent. The authors 
failed to establish any connection between the protein binding of these 
anti-infectives and their systemic effects. The relative binding power 
of the protein for the drug was not established nor was the possibility 
of displacement within the drug-protein complex. It is the consensus 
that most drug-protein complexes are therapeutically inactive. 
In 1960-1961, Anton, using equilibrium dialysis, confirmed that 
in vitro protein bound sulfonamides were devoid of antibacterial activity 
and that the binding activity varies greatly between mammalian species. 
He also presented in vivo evidence that the distribution of sulfonamide 
in the rat could be modified by competitive interference with its bind-
ing to plasma protein by other drugs, i.e. sulfinpyrazone, ethyl bis-
coumacetate, phenylbutazone, and iophenoxic acid. The total number of 
binding sites per molecule of human serum albumin for a sulfonamide was 
determined by Clausen (1966). Clausen also reported that other plasma 
proteins (prealbumin, glycoproteins, and alpha 2-macroglobulin) possessed 
secondary binding properties. 
Eichman et al (1962) demonstrated that xanthine molecules 
(caffeine, theopbylline, theobromine, etc.) formed drug-albumin complexes. 
Their results indicated that the extent of the binding was partially 
dependent upon the hydrogen ion concentration of the system, and the 
acid strength ot the drug. 
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The inactivation of penicillins F, G, K, and X by human and 
rabbit serum protein interaction was revealed by Eagle (1947). Keen 
(1965) found that the binding of these antibacterials showed considerable 
variation between oxen, goats, horses, sheep, and pigs. According to Keen, 
these differences may be accounted for by the average plasma concentra-
tions of albumin, differences in affinity for the drug molecule, and 
ionic constitution of the different plasmas. Temperature variation has 
been characterized as another factor operant in the binding of penicillins, 
calcium, and anionic dyes. In 1966, Keen reported that sulpb.a.methoxy-
pridazine, phenozmethyl penicillin, and phenol red could be displaced 
from serum albumin by several anionic drugs This displacement by agents 
such as phenylbutazone and salicylate showed specificity. Furthermore, 
Keen determined the number of binding sites for phenoxymetbyl penicillin 
and benzylpenicillin to bovine serum albumin. 
In 1954, Goldbaum and Smith investigated the in vitro binding 
characteristics of several barbituric acids to bovine serum albumin using 
ultrafiltration. Among the barbiturates studied were tbiopental, seconal, 
pentobarbital, phenobarbital and barbital. Their results showed that 
gradually increasing the length of the substituted alkyl side chain from 
two to six carbons increased the percent of the drug bound. Hence, those 
drugs having the shorter duration of pharmacological action bad the 
greatest fraction bound. Variation of pH, albumin concentration, and 
drug concentrations produced: 
1) maximum drug-albumin complex at approximately pH 7.8; 
4. 
2) 
3) 
an increase in bound drug with increased albumin concen-
tration which plateaued near 4%; 
maximal and minimal·barbit}f'ate-albumin interaction at drug 
concentrations of 25 x 10- and 1 x lo-3 M respectively. 
They demonstrated that bound barbiturates could be partially displaced 
from the drug-albumin complex by addition of other barbiturates and 
dissimilar organic anions. In vivo distribution and in vitro tissue 
homogenate studies in the rabbit generally indicated the highest binding 
of the barbiturates occurred in plasma liver heart kidney lung brain 
muscle red cells. Finally, they estimated the number of binding sites 
on bovine serum albumin for the barbiturates. 
The work by Goldbaum and Smith provided evidence that barbi-
turate binding is "related to pH", drug concentration, and protein 
availability. Also, binding in vitro seems to be related in part to the 
distribution of drugs in vivo. 
Employing dosages approximately five to ten times that used 
therapeutically, Lous (1954) examined the fate of three barbituric acids 
in man. Using three to four normal subjects per drug, his work indicated 
that the highest plasma concentration of barbital (B), allypropymal (A), 
and phenobarbital (P), occurred between four to eight hours, three to 
nine hours, and twelve to eighteen hours, respectively. A~er adminis-
tration, the drugs were eliminated from plasma following an exponential 
curve with total urine excretion for B, A, and P being 75-95%, 9-18%, 
and 13-37% respectively. The renal clearance was shown to be "independent 
of plasma concentration but dependent upon urinary flow". Lous found, by 
ultrafiltration, experiments, that the percent of barbiturate bound to 
5. 
plasma was 95% (88-104) for barbital, 50% (33-71) for phenobarbital, and 
60% (54-65) for allypropymal. 
Also, in 1954, Taylor et al investigated the binding of thio-
pental by rabbit plasma in vivo and in vitro. These data indicated that 
the amount of drug bound in vitro closely resembled the amount bound in 
vivo. They also demonstrated that as the concentration of the thiopental 
increased, the percentage of the thiopental bound decreased, resulting 
in an enhancement of the sleeping time duration. 
Waddell and Butler (1957) delved deeper into the distribution 
and excretion of·phenobarbital in dog, mice and man, stressing the effects 
of pH alteration upon the parameters studied. In contrast to the results 
obtained by Goldbaum and Smith, these authors presented in vitro pheno-
barbital binding data obtained by dialysis which indicated that the 
percentage of the drug bound was only slightly affected by pH within the 
normal physiological range found during acidosis and alkalosis. Further-
more, they stated that "in a 4 gm. per 100 ml. solution of albumin, the 
proportion of phenobarbital bound is almost independent of the pheno-
barbital concentration over the range of 20 to 100 mg. per liter". They 
also stated that binding by "human serum albumin did not differ signifi-
cantly from bovine albumin". In vivo experiments in dog, mice and man 
revealed that after precipitation of acidosis, induced by co2 inhalation, 
and alkalosis, by hyperventilation or intravenous infusion of NaHC03, 
plasma phenobarbital concentrations fell as blood pH decreased. Experi-
ments measuring the effects of pH on phenobarbital -induced anesthesia 
in mice indicated that alkalosis lightens phenobarbital anesthesia by 
6. 
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decreasing drug concentration in the brain. Thus, tissue/plasma con-
centration varies reciprocally with blood pH. Finally, Waddell and 
Butler presented data showing that the renal clearance of phenobarbital 
was similar in man and dog; "The clearance of phenobarbital increases with 
increasing urine flow in acid or alkaline urine, but at any given rate 
of flow the clearance is much higher in alkaline than in acid urine." 
The work cited here indicates that the pharmacological action 
of many drugs is closely related to plasma protein binding and binding 
site availability. A number of these papers have reported that drug 
binding to these proteins, whether albumin, globulins, glycoproteins, etc., 
is a function of pH, drug or protein concentration. Duration of action 
and metabolic fate are apparently influenced by these phenomena. The 
investigations involving phenobarbital by Goldman and Smith, Lous, Waddell 
and Butler provide evidence showing that the drug is primarily bound by 
serum albumin. However, the effects of variation in drug concentration, 
serum albumin concentration, and pH upon phenobarbital binding are in 
some instances contradictory. Also, binding site availability on human 
serum albumin for phenobarbital has not as yet been established. 
Inconsistencies in previous reports on phenobarbital binding 
by serum albumin suggested the need for clarification in this area. The 
ratio of moles of drug bound per mole of albumin calculated by Goldbaum 
and Smith was determined, using a value of 14.5 x 10-5M for their bovine 
albumin concentration. On recalculation, it appears that. this value 
-5 
should have actually been 14.7 x 10 M. The larger value could have 
resulted in a lower binding site estimation. Waddell and Butler stated 
7. 
that the binding of phenobarbital to human serum albumin was affected 
only to a slight degree by pH and that it was nearly independent of pH, 
whereas Goldbaum and Smith state that phenobarbital binding to albumin 
is related to pH. Waddell and Butler reported that alkalosis induced in 
mice increased the median anesthetic dose of phenobarbital. They also 
observed a decrease in phenobarbital plasma concentrations after inducing 
acidosis in the dog. These findings do not appear to be in concert with 
their in vitro data; although Waddell and Butler indicated that they 
performed some experiments involving the binding of phenobarbital to 
hu.~an serum albumin, they failed to present any data documenting their 
findings. The only direct data concerning the binding of phenobarbital 
to human serum proteins were reported by Lous. Lous estimated that in 
vivo binding of the drug concentration found in human serum ranged 
oe::;ween 33-71%. However, the upper and lower values were obtained in 
a si~gle individual. He did not determine the percent of protein in 
tLe serum nor the blood pH of his samples. Therefore, research involving 
tl:cse problems entailed a confirmation and clarification of the charac-
teristics exhibited by human serum albumin binding of phenobarbital sodium 
when drug concentration, albumin concentration and pH were varied. A 
second phase included the determination of the number of binding sites 
per molecule of albumin available to the drug. These data were further 
examined in regard to implications as to pharmacological effect in humans. 
8. 
CHAPTER II 
MCl.TERIAI.S AND METHODS 
In this study, experiments were designed to determine the 
percentage of drug bound in vitro to human serum albumin (HSA) while 
varying specific physical and chemical conditions. However, all experi-
ments were conducted in an in vitro system approximating the normal in 
situ HS.A environment as closely as possible. 
The percentage of drug bound to HSA was determined by a modi-
fication of the equilibrium dialysis procedure of Anton (1960). Equili-
brium dialysis confines the protein component within a bag formed from 
a semi-permeable membrane. This membrane allows unbound drug molecules 
to freely diffuse into the solution surrounding the bag until equilibrium 
is attained. When unbound drug concentrations on both sides of the 
membrane become equal, any drug increment in the protein compartment is 
presumed to represent drug bound to protein. The concentration and 
percent of drug bound is determined as follows: 
l) Concentration of bound barbiturate = Concentration of barbiturate 
in the bag minus concentration 
of barbiturate in dialysate 
2) % bound barbiturate = Concentration of bound barbiturate x 100 Concentration of barbiturate in bag 
The technique of equilibrium dialysis provided an uncomplicated method 
for the study of protein binding. It also allowed the convenience of an 
overnight binding reaction and easily controlled temperatures. 
Phenobarbital was assayed by the ultraviolet, spectrophotometric 
method of Goldbaum (1952), and Goldbaum and Smith (1954). This procedure 
9. 
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~ combines precision, specificity, simplicity and sensitivity for the 
measurement of microgram quantities of phenobarbital in saline, blood, 
serum, and urine solutions. To minimize experimental variance due to 
pipetting errors, determination of data from standard curves, and other 
extraneous variables, each experimental point was established on the basis 
of three separate determinations. Ea.ch such determination was conducted 
in duplicate. The average and standard error of the mean for each set of 
phenobarbital values was calculated. Protein concentrations were deter-
mined by the procedure of Gornall et al (1948). 
Preliminary Experiments 
Pilot experiments were conducted to assure that no interference 
in binding or assay resulted from the cellulose dialysis tubing. In 
system one, 0.001 M phenobarbital Na in Sorensen's M/15 phosphate buf'fer 
solution was placed in the dialysis tube (outer phase) while the dialysis 
bag (inner phase) contained only the buf'fer. In a second system, the 
phases were reversed. A buf'fer solution containing phenobarbital equal 
in amount to that in the tube of system one was placed in the bag. This 
bag was then put into a dialysis tube containing only buf'fer solution. 
A~er 16 hours dialysis, the buf'fer solutions in the tubes and bags of 
both systems were analyzed for phenobarbital concentration. 
Additional experiments estimated the minimal amount of time 
necessary to attain system equilibrium. The above procedure was repeated; 
however, a three percent human serum albumin-buf'fer solution was placed 
into the dialysis bags. The dual systems were then dialyzed and assayed 
after eight, twelve and sixteen hours. Minimal equilibrium time was 
10. 
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determined to be twelve hours. 
Previous work by Goldbaum and Smith (1954) using ultrafiltra-
tion indicated that equilibrium values for barbiturate binding to bovine 
· ff t d b t t ranging from 4° - 4o0c. albumin was una ec e y empera ures Experi-
0 
ments were conducted at 37.5 c. and at room temperature, confirming the 
above results. Thus, for convenience, equilibrium dialyses were carried 
out overnight through a period of 16 to 17 hours at room temperature. 
A final set of preliminary experiments was conducted to confirm 
the sensitivity of the assay and the percentage of phenobarbital Na 
recovered. The partition coefficient was determined as described by 
Martin (1962) and employed to calculate the theoretical extraction and 
percentage recovery of the drug. 
RSA-Phenobarbital Binding Experiments 
To ascertain a picture of HSA binding capacity and estimate' 
the number of binding sites per molecule of albumin available to pheno-
barbital, the effect of drug concentration variation upon binding was 
studied. Concentrations ranging from that considered therapeutic to those 
causing toxic reactions were investigated as follows: 
a) -5 12.5 x 10 M e) 2 x lo-%1 
b) 25 x l0-5M f) 4 x 10-; 
c) 5 x l0-4M. g) 8 x lo-.\ 
d) 1 x 10-~ 
T::c: 12.5 x 10-5M concentration was employed in all other experiments. 
'l'his concentration was assumed to be therapeutically equivalent to that 
f .. ,_.._, ___________________________________ __ 
11. 
found in a nonnal 70 Kg. individual after administration of 150 mg. of 
phenobarbital. 
The normal range of arterial blood pH is 7.35 - 7.45, "any pH 
below 7,35 or above 7.45 is generally defined acidosis and alkalosis 
respectively", (Woodbury, 1965). Many acute and chronic disease states 
clinically reveal an acid-base disturbance; therefore effects of pH 
variation (6.6 - 7.8) upon binding were investigated. A pH of 7.4 was 
maintained in all other experiments. 
The effects of varying concentrations of ,HSA (l to 6%) on 
binding were also examined since there are clinical conditions in which 
HSA variations from normal may occur. For all other experiments, 3.o'fo 
HSA was utilized. 
Finally, the number of binding sites per molecule of human 
serum albumin was estimated using the procedure described by Karush (1950). 
System Components and Procedure 
Unless specified, all solutions were made up using glass dis-
tilled water and employed at room temperature. All compounds were weighed 
on an analytical balance to the nearest 0.1 mg. 
Dialysis Bags (Scientific Products #Dl615-2) 
The dialysis bags were prepared from high purity, seamless, 
re~~enerated cellulose tubing (150 mm. in length and 28 mm. in width). 
T~2 tubing was rinsed in glass distilled water, then washed for 15 minutes 
0 in 90 C. glass distilled water, and finally rerinsed three times. Washing 
was done to eliminate any substances in or adhering to the cellulose 
which might interfere with the analytical procedure. The tubing was 
12. 
double knotted and trimmed at the distal end while the proximal portion 
was tied securely to the end of a glass tube with blanched nylon thread. 
The dialysis bags measured aJ?proximately 4.5 cm. from the end of the 
glass tube to the :proximal end of the knot. All bags were tested for 
leaks by submerging the bags in water and blowing through the proximal 
end of the glass tube, absence of bubbles being indicative of positive 
closure. 
Dialyzer Container 
The dialyzer container consisted of a Pyrex (Corning ://9820) 
25x100 mm. culture tube, Bacti-Capall (Scientific Products #T-1395-4) 
and a one hole neoprene stopper (18x24 mm), through which was placed 
Pyrex glass tubing (6 mm I .D. x 55 mm lg.). The glass tube was fire 
polished at one end and blunted to form a lip at the distal end. The 
proximal end of the glass tube then provided a porthole used to admit · 
the HSA into the dialysis bag while the distal lip provided a ledge to 
which the bag was secured. 
The Dialysis System Assembly Procedure (Figure l) 
1. A dialysis bag was tied to the glass tube of the neoprene 
stopper and allowed to dry. 
2. Ten ml. of the appropriate phenobarbital Na/buffer solu-
tion concentration was pipetted into a culture tube and the base of the 
tube inserted into a Bacti-cap which :provided a standu:p platform. I 3. Three ml. of the appropriate BSA/buffer concentration was 
J pi:oetted into the dialysis bag through the glass tube insertion port. 
I 
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4. Tne neoprene-dialysis bag assembly was then inserted into 
the culture tube. The glass tubing at the proximal end of the stopper 
assembly was depressed until the HSA solution meniscus in the bag was 
at a level equal to that of the culture tube phenobarbital Na solution. 
5. A Bacti-cap was placed over the head of the entire assembly, 
sealing in the contents. The contents were dialyzed for 16 hours at room 
temperature in a metabolic shaker at 80 strokes/min. using a 1-1/2 inch 
stroke. 
6. At the end of this period, the contents of both the dialysis 
bag and dialysis tube were analyzed for phenobarbital and protein con-
centration. 
Human Serum Albu.min Solution (Calbiochem-Pentex Lot #17, 21, 23) 
Electrophoretically pure crystalline human albumin was dissolved 
in the appropriate M/15 buffer and refrigerated. The HSA solutions were 
used within 24 hours. 
Phenobarbital Sodium (Mallinckrodt Chemical Works Lot #DET) 
The powder was dissolved in the phosphate buffer at the con-
centrations indicated on page ll. The drug was solubilized in HSA 
solution at a concentration of 0.001 M when determining system equilibrium. 
Borate Buffer 
74.554 @nS· of KCl, reagent grade, and 61.844 gms. of boric 
acid, reagent grade, diluted to one liter with water. It was then stored 
at room temperature for 24 hours and filtered. 
15. 
Sorensen's M/15 Phosphate Buf'fer (Hepler, 1960) 
Sorensen's M/15 Phosphate Buf'fer was prepared by mixing the 
appropriate quantities from stock solutions of: 
l. M/15 Potassium Acid Phosphate (KH2Po4), 9.o8 gm. qs. to l liter. 
2. M/15 Disodium Phosphate (Na2HPo4), 9.47 gm. qs. to 1 liter. 
Sodium Hydroxide Solutions: 
Sodium hydroxide solutions were prepared by diluting a comm.er-
cially available lON Analytical Reagent Grade Sodium Hydroxide solution 
with glass distilled water. 1 N sodium hydroxide was used for washing 
the chloroform extracting solvent. Approximately 0.36 N was used in 
the phenobarbital analysis. The alkalinity of this solution was adjusted 
to a pH of 10.4 by adding NaOH and borate buffer in a 2:1 ratio as 
required. 
Chloroform 
Reagent grade chloroform was washed with 1 N sodium hydroxide 
followed by two rinsings with glass distilled water. For every liter of 
solvent, 100 ml. of wash solution was used. Only the volume necessary 
for daily use was washed because the chloroform tends to decompose upon 
standing. 
Biuret Reagent (Harleco Lot #70101} 
Tbe reagent was prepared in accordance with the procedure 
described by Gornall et al. The preparation consisted of a modified 
alkaline copper'tartrate stabilized with potassium iodide. 
16. 
(For a detailed description of the procedures quoted, see the Appendix). 
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CHAPTER III 
RESULTS 
Prior to commencing any experiments on the binding of pheno-
ba ::'!Jital, we attempted to validate the analytical procedure for barbi-
turates as described in 1952 by Goldbaum (see Appendix). The analytical 
procedure involved an initial series of four extractions of phenobarbital 
by CHC13 from Sorensen's Buffer following addition of HCl. Following 
this step, the pooled CHC13 extract was re-extracted by NaOH. Extraction 
of phenobarbital in this second phase was virtually complete. Using this 
procedure, the phenobarbital recovery was found to be approximately 
92-93'%· A theoretical recovery of 93.8% was calculated for phenobarbital. 
Thus the theoretical and actual recovery of the barbiturate were com-
parable. 
Employing a semi-log plot, Figure 2 illustrates the effects 
of varied barbiturate concentrations upon the percentage of phenobarbital 
bound by human serum albumin (HSA). The amount of drug bound increased 
while the percentage bound diminished as phenobarbital concentrations 
increased. Thus, at a concentration considered therapeutically effec-
tive, 12.5 x io·5M, a high fraction of the drug was bound. The percent 
of phenobarbital bound at 0.5 - 8 x 10-3 M, concentrations which would 
appear to be toxic or lethal were significantly less bound than at 
-5 12.5 x 10 M (Table 1). 
18. 
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TABLE I , 
Effect ot Varying Phenob&rb1tal Na Concentration 
on Percentage ot Drug Bound b1 HSA at pH 7.4 
Dru~ Concentration p_o-5 M) 
12.5 
25.0 
50.0 
100.0 
200.0 
400.0 
aoo.o 
'lo Drug Bound 
i:S.E.* 
53.0 !0.58 
56.9 to.54 
46.8 t0.40 
43.6 :o.66 
39.4 to.70 
37.4·t1;01 
27.7 tl-58 
Level of Significance 
0.01 
0.001 
0.001 
0.001 
0.001 
0.001 
* S.E. represents the standard error of the mean percentage of drug bound 
The changes in phenobarbi ta1 binding by human serum albumin 
{HSA) binding due to pH alterations are depicted in Figure 3. The 
fraction of barbiturate bound declined as the hydrogen ion concentration 
was increased. The sharpest decrease in binding occurred between pH 7.2 
and 7 .4. According to Woodbury {1965), any pH above 7 .45 or below 7. 35 · 
indicates alkalosis and acidosis respectively. Table II indicates tbat 
the amount of drug bound was significantly less at pH's representing 
acidosis than at normal physiological pH. Above pH 7.4, the percentage 
of drug bound began to plateau. However, at pH's represen~ing alkalosis, 
a slight increase in phenobarbital binding occurred which became signi-
ficant at pH 7 .8. In the pH range investigated, the drug binding affinity 
of the protein appeared to decrease as the pH was lowered. 
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EFFECT OF pH VARIATION ON 3% HSA BINDING 
OF 12.5 X 10-5 M PHENOBARBITAL Na 
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pH 
Acidosis 
7.2 
7.0 
Alkalosis 
7.6 
7.8 
TABLE II 
Effect of pH A~teration on 3% HSA Binding 
of 12.5 x io-5 M Phenobarbital Na 
% Drug Bound tS • E. 
53.0 ±0.76 
Level of Significance 
38.6 t0.23 
34.3 to.70 
53.2 to.30 
57.8 t0.24 
0.001 
0.001 
N.S. 
0.01 
Changes in the percentage of phenobarbital bound at various 
concentrations of human serum albumin are portrayed in Figure 4. A pro-
gressive increase in the portion of the drug bound occurred as the con-
centration of HSA was increased. The sharpest rise in binding occurred 
between two and three percent HSA after which percentage of drug bound 
began to plateau. Little difference in binding was observed between 
three and four percent protein concentration. When considering the moles 
of drug bound per mole of albumin, the fraction of phenobarbital bound 
was generally reduced as albumin concentrations increased (Table III). 
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EFFECT OF MSA CONCnlTRATION VARIATION ON 
BINDING Of 12.5 )( 10-6M PHENOBARBITAL Na 
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TABLE III 
Effeot of Val'lins HS.A Concentration on Binding 
of 12.5 x 10~.< M Phenobarbital at pH 7.4 . 
% Drug Bound 
-.t S.E. 
2i.8 +o.82 
32.1 ±0.74 
53.0 :to.58 
58.8 :t0.27 
63.5 :to.59 
Moles Drug_5 Bound x 10 
2.72 
4.0l 
6.62 
7.35 
7.94 
Cone. HSA Fraction Drug 
Moles (10-5) Bound/Mole HSA* 
14.5 
29.0 
43.5 
58.0 
86.8 
0.19 
0.14 
0.15 
0.13 
0.09 
*Assuming a molecular weight of 69,000 for HSA 
The reduction in the fraction of phenobarbital bound per mole 
of albumin can be attributed to a dilution of the drug in the albumin. 
As the albumin concentration was increased, the number of binding sites 
was increased while the barbiturate concentration remained constant. 
To estimate the number of binding sites per molecule of 
albumin, the moles of drug bound per mole of albumin (r) was determined 
for several concentrations of the drug (see Appendix). These ratios were 
then related to the molar concentration of_ free drug present (c) by 
making a lineal plot of r/c vs. r. To minimize experimental error which 
might have resulted due to techniques employed and to improve the accuracy 
of binding site estimation, the percentages of drug bound used to calcu-
late r were determined from Figure 2, as indicated in Table rv. The 
semi-log plot allowed the determination of values from a straigh"l:; line. 
The molecular weight for human serum albumin was assumed to be 69,000 
(Phelps and Putnam, 1960). The ionic strength of the phosphate buffer 
at pH 7.4 was calculated at 0.17 arbitrary units (Martin, 1962). The 
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TABLE IV 
Values Utilized for Characterization of 
Phenobarbital Binding Sites 
Initial Final Free Amount Moles Bound 
Drug Cone. <f, Drug Drug Cone. (c) Drug Bound Drug/mole 3 3 (10-5 M) Bound (10-5 M) (10-5 M) HSA (r) r/c x 10 r/c x 10 (f) 
12.5 53.7 5.8 6.7 0.15 2.59 1.44 
I\) 12.4 12.6 2.33 Vl 25 50.3 0.29 1.35 . 
50 46.9 26.6 23.4 0.54 2.03 1.15 
100 43.2 56.8 43.2 0.99 1.74 l.o4 
200 39.9 120.0 79.8 1.83 1.52 0.91 
400 36.8 253 147.0 3.38 1.34 0.87 
8oo 33.3 534 266.0 6.ll 1.14 0.85 
concentration of human serum albumin was 43.5 x 10-5 M (3%). 
Figure 5 presents the graphical estimation of phenobarbital 
binding sites per molecule of albumin. According to Karush (1950), 
Scatchard (1949, 1950), and others, homogeneity of binding sites produces 
a straight line plot. When the line is extrapol.ated to the ordinate and 
abscissa, the intercepts equal nK and n respectively (see Appendix). If 
the r/c vs. r relationship produces a curved line, two alternatives are 
present. The deviation from the straight line may be due to electro-
static factors or the binding sites are heterogeneous. 
The plot of these data produced a curved line, Figure 5. 
Therefore, we replotted the data using the electrostatic interaction 
correction factor. The formula for electrostatic interaction is r/c (t) 
2w(Zp+r) · 
where f equals e (Keen, 1966). The factor (e) is the loglO of 
the natural logarithm and (w) is the electrostatic parameter taken as 
0.025, extrapolated from Tanford et al (1955). According to Goldstein 
(1949), the isoelectric point of albumin is 4.9 and carries a net nega-
tive charge at pH 7.4. Consequently, the charge on the protein (Zp) is 
taken as -12 (McMenamy, 1968). A plot of r/ c (f) vs. r, Table 'IV, 
produced a curved line, Figure 6. 
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r represents the moles of drug bound per mole of albumin, and 
c equals the final free drug concentration (10-5 M). 
Since we failed to demonstrate the presence of homogeneous 
binding sites, an aesuiiwtion ot heteroseneous binding sites for pheno-
barbital was made (see Appendix). Resolution of the binding curve 
(Figure 5) indicated two components corresponding to sites, n1 and n2 • 
Table V shows the values obtained for the albumin molecules binding sites 
and their association constants for phenobarbital. 
TABLE V 
Values Detennined for the Number of 
Phenobarbital Binding Sites (n) on the 
Human Serum Albumin Molecule and Their 
Association Constants (K) for Phenobarbital 
Sites 
Primary binding sites 
Secondary binding sites 
Total binding sites 
.n 
0.95 
14.05 
15 
nK 
950 
1750 
2700 
K 
1000 
124 
The relationship between free and bound drug concentration for 
these groups of sites is expressed by an equation calculated by Karush (1950 
1 + ~c 
When the above values were substituted in the equation, the 
broken line in Figure 5 was plotted. This curve approximates that ob-
tained with the experimental data. Extrapolation of both curves estimates 
the total number of binding sites to be approximately 15. The data suggest 
a primary group .of sites w1 th a greater affinity for phenobarbital and a 
pt L T 
~ 
I 
' ~ 
se.::onda.ry more numerous group with a lesser affinity as indicated by the 
differences in the group association constants. 
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DISCUSSION 
The response of living systems to chemical stimuli such as drugs 
is often widely varied between and within the species and frequently with-
in an individual organism. 11Most of the variation attending the use of 
drugs, especially in therapeutics, lies in the wide ranges of physical, 
biochemical, and pathological conditions that con:f'ront the drug when it 
is administered to a living organism" (Condouris, 1965). Plasma-protein 
binding of drugs, particularly by serum albumin, demonstrates a notable 
involvement in drug-response variation. Drug binding by albumin can alter 
therapeutic effectiveness, delay metabolic transformation or excretion, 
and participate in drug interaction. The slow release of a bound drug 
may prolong drug blood levels, resulting in sustained therap~ or the 
bound complex may act as a protective carrier system by which a drug can 
be transported to or removed from its site of action. (Tonnesen, 1956; 
Anton, 1960; Keen, 1966; Meyer and Guttman, 1968; Goldstein, 1949.) The 
binding of drugs by albumin is related to environmental pH, albumin con-
centration, and drug concentration (Goldstein, 1949; Goldbaum and Smith, 
1954). Consequently, variations in the physical, biochemical, or path-
ological condition of an organism which change pH or albumin concentra-
tions can influence drug binding and alter therapeutic effectiveness. 
In 1954, Lous estimated the percentage of phenobarbital bound 
in vivo by serum proteins. He employed three normal human subjects and 
repeated the experiment in one of the subjects to obtain four values. 
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Each subject received 750 mg. of the barbiturate orally. Using ultra-
filtration, he found that s~~ proteins bound phenobarbital at a level 
of 33 - 71% (50 :t8%). Unfortunately, Lous did not report the blood pH 
or serum protein content for any of the subjects. Nevertheless, the 
calculated average of 50'/o was fairly close to results we reported. Our 
data indicated that approximately 43 - 47% of a comparable in vitro con-
-4 -3 
ccntration, between 5 x 10 and 1 x 10 M, was bound to albumin alone. 
Th"-.:.s, there appears to be some relationship between in vivo and in vitro 
phl:~nobarbi tal binding. It has been reported that minor secondary binding 
und sometimes primary binding occurs with other serum proteins such as 
preaJ.bumin, alpha and gamma globulins, and glycoproteins (Goldstein, 1949; 
Clausen, 1966; Meyer and Guttman, 1968). However, album1n is considered 
the primary binding entity for most drugs including phenobarbital. 
Barbiturates in sedative or hy:pnotic doses act principally at 
the level of the thalamus and the ascending reticular formation, inter-
fering with impulse transmission to the cortex (Cutting, 1967). These 
drugs are capable of depressing many biological :f'unctions and are con-
sidered unspecific in their effects. Although little is known about 
their mechanism of action, barbiturates are only partially ionized at 
biological pH's. Available information indicates that the free acid 
(undissociated) form is responsible for the depressant effects. (Hardman 
et al, 1959; Sharpless, 1966). "Moreover, the drugs cross the cellular 
membrane only in the form of undissociated molecules" (Maynert, 1965). 
Examination of our pH data indicates a sharp increase in 
phenobarbital bound as the pH is increased, 35% at pH 7.2 to 53% at 7.6. 
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As the hydrogen ion content decreases, the fraction of the barbiturate 
bound substantially increases and the amount of drug available to produce 
an effect is diminished. 
Waddell and Butler reported a 6~ difference in the fraction of 
phenobarbital bound by albumin in vitro between pH 7.2 and 7.6. They 
stated that "binding is affected only to a small degree by pH", and that 
"the binding is nearly independent of pH". Nevertheless, their in vivo 
experiments in mice indicate a 20% increase in the median anesthetic dose 
of phenobarbital after NaHC03 induced al.kalosis. Waddell. and Butler also 
observed a decrease in plasma phenobarbital concentration when acidosis 
was induced by 002 in dogs. Assuming that the drugs cross cellular mem-
branes only in the fonn of undissociated molecules and that the bound 
fonn is inactive (Goldstein, 1949; Maynert, 1965), the in vivo and in 
vitro· results and conclusions of Waddell. and Butler appear to be incon-
sistant. On the other hand, our results and those of Goldbaum and Smith 
correlate nicely with the in vivo data of Waddell. and Butler. The in-
fonnation reported above indicates that phenobarbital binding as well 
as drug response are apparently pH dependent. 
The binding of an anionic drug molecule by albumin can be 
ascribed to the availability of the free imidazole,f-amino, and guanido 
groups of the basic amino acids - histadine, lysine, and arginine, res-
pectively. 
The dissociation constants for phenobarbital and the amino 
acids are represented by their pKa values. The pKa for phenobarbital, 
a weak acid, is. 7.4 (Martin, 1962). The pKa's for the imidazole group 
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of histadine, the f -amino group of lysine, and the guanido group of 
arginine are 5.6 - 7.0, 9.4 - 10.6, and ll.6 - 12.6 (White, Handler, and 
Smith, 1964). The acidic and basic dissociation constants may be cal.cu-
lated by substitution in the following equations: 
pKa = pH + log non-ionized acid 
ionized acid 
ionized base pKa = pH + log 
--------
non-ionized base 
(l) 
(2) 
Examination of the pKa, pH and the equation involved provides a basis for 
determining the extent of drug or amino acid ionization. 
As the hydrogen ion concentration in a solution containing 
phenobarbital is decreased, the amount of the drug ionized is increased 
(equation l). Thus, the anionic form of the phenobarbital molecule be-
comes more available for binding as the pH is increased from 6.6 - 7.8. 
In contrast, this alteration of pH results in a positive charge on the 
free groups of the basic amino acids {equation 2). The presence of 
increasing amounts of the anionic and cationic charged molecules in the 
solution provides for increases in the drug-protein binding. Since the 
imida.zole group las the lowest pKa, it is likely that this is the group 
primarily responsible for the binding of phenobarbital to human serum 
albumin. 
Like Goldbaum and Smith, many researchers have reported a 
reversal of the fraction of drug bound above pH 7.8. This decrease in 
association above pH 7.8 is rationalized by Eichman et al (1962). They 
assume: 1) the occurrence of a specific interaction between a 
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"proteinated site" on the albumin and the drug, or 2) a change in the 
configuration of the binding sites "resulting from the neutralization of 
a proteinated group on the protein". Either or both may result in a 
disruption of the drug-protein complex. They point out that ~--a.mine groups 
dissociate in the pH range where binding reversal transpires, and tbat 
"it is quite possible tbat neutralization of such groups is related to 
the marked decrease in the interaction". 
Our pH data and that of Goldbaum and Smith suggest tbat change 
in the blood hydrogen ion content may affect the dosage at which pheno-
barbital and other barbiturates a.re therapeutically effective. Binding 
differences over a nonnal pH of 7.35 - 7.45 amount to approximately 4.5~ 
in vitro. Disease states evoking disturbances in acid-base metabolism 
leading to acidosis or alkalosis such as renal disorders, respiratory 
disorders (tuberculosis, emphysema), types of adrenocorticism, or diabetes 
mellitus, provoke significant pH alterations. Although barbiturates may 
often be contraindicated in these conditions, sedative and hypnotic doses 
o:f' phenobarbital are administered to relieve insomnia and anxiety prior 
to knowledge of their etiology. Undissociated phenobarbital availability 
appears to be a :factor in drug dose-response relationship. Consequently, 
aey disease states evoking pH changes would contribute to the problems 
of drug dosage variability between and within patients. 
The concentration o:f' albumin in serum between individuals is 
highly varied. Altman and Dittmer (1961), using reports published in the 
1950' s, compiled a table showing a range of 2. 0 - 4. 5 g/100 ml. Other 
sources suggest .an average concentration of 3.5 g/100 ml. The consensus 
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places the average HSA concentration between three and four percent. Little 
difference in binding was observed (5 percent) between HSA concentrations 
of 3 to 4 percent. A sharp decrease in the amount of drug bound was ob-
served below 3 percent. Our work supports the findings of Goldbaum and 
Smith. We all observed that 3 percent albumin bound approximately 43~ 
of the phenobarbital. Differences between human serum albumin and bovine 
serum albumin seem small and many drugs are bound to approximately the 
same extent by both. "In general, however, the complete unpredictability 
of species differences and variation of relative binding power with 
different drugs dictate caution in transferring interaction data between 
species 11 (Goldstein, 1949; Tanford, 1955). The results obtained appear 
to indicate that HSA expresses its greatest influence upon the drug binding 
at concentrations below 3 percent. More subtle binding changes occur 
above 4 percent. Conditions such as dehydration, renal disease, liver. 
disease, and malnutrition, lead to HSA alterations. Changes in albumin 
concentration could be a participating factor in the regulation of pheno-
barbital dose-response by controlling the number of albumin molecules with 
available binding sites. 
Given a specific pH and HSA concentration, increasing pheno-
barbital concentrations provide a larger quantity of undissociated drug. 
Consequently, toxicity results when a sufficient amount of the free acid 
becomes available. As the phenobarbital concentration increased, the 
moles of drug bound per mole HSA ratio increased proportionately until 
-5 
concentrations approximating toxic levels were attained. At 100 x 10 M, 
this proportionality began to decrease. Although the percentage of drug 
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bound at 8oo x l0-5 M was low, the ratio indicates that approximately 40 
times more drug was bound per molecule of BSA at this concentration than 
at 12.5 x l0-5 M (Table IV).· .. It would appear that the presence of pheno-
barbital may affect the affinity of the protein for the barbiturate. The 
decrease in proportionality may be attributed to binding site saturation 
and/or a distortion of binding site configuration due to saturation. 
When the environment of the albumin is altered, the response 
of the' organism to phenobarbital can become quickly magnified. Higher 
concentrations of the drug not only provide more of the free acid fonn 
but can cause depressed respiration leading to respiratory acidosis. This 
decrease in pH would result in a further magnification of the phenobarbital. 
response. 
Karush together With Goldbaum and Smith have stressed the im-
portance of the number of binding sites per molecule of protein (n) in. 
the drug-protein complex. It was estimated from these results that human 
serum albumin has a totai n of 15 for phenobarbital. There was a primary 
class of sites (n1 = 0.95) and a more numerous secondary class (~= 14.05). 
Goldbaum and Smith determined that bovine serum albumin (BSA) had 22 n. 
The BSA sites consisted of a primary group with a smaller n1 (0.3) and 
a larger secondary n2 (21.7). Moreover, the~ association constant was 
extremely high when compared with ours (287,000. vs. 1000). A comparison 
between secondary association constants showed some agreement, 90 vs. 124. 
Thus, BSA not only had more binding sites per molecule albumin than BSA 
but the overall affinity for binding phenobarbital was stronger. 
Given .constant physiological and biochemical conditions, it is 
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tempting to attribute species differences in phenobarbital response to 
the number and character of the binding sites found on serum albumin. 
However, binding data such as"reported in this disse~ation have not be-
come available for albumin of species other than bovine. 
In conclusion, a comparison between these data and results ob-
tained by Goldbaum and Smith, Taylor et al (1954), Waddell and Butler, 
and Lous, provides a correlation between in vitro and in vivo binding of 
phenobarbital by serum albumin. The drug-protein complex is a :f'unction 
of the number of binding sites available. But the extent of phenobarbital 
binding is dependent upon pH and related to the serum albumin concentra-
tion and the drug concentration. Any disease states altering these para-
meters alter phenobarbital binding by HSA and may produce variations in 
the drug dose-response relationship. 
SUMMARY 
1. Phenobarbital binding is related to hydrogen ion concentration, being 
maximal at about pH 7 .8. The percent of drug bound sharply decreased 
below pH 7.35. 
2. At a given concentration of phenobarbital, the fraction of drug bound 
approaches maximum with increasing albumin concentration. However, 
the fraction of bound drug per mole HSA diminishes. 
3. As the phenobarbital concentration increases, the fraction bound 
decreases; however, more drug is bound per molecule of HSA. 
4. A total number of 15 binding sites per molecule of HSA is estimated 
for phenobarbital. Two classes of sites were determined, a primary 
eroup with high affinity and a secondary group with much less af':f'inity. 
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5 • The percentage of phenoba.rbi tal bound by HSA in vitro was found to be 
similar to previously published results obtained in vivo. 
6. Alterations in physical, '~d chemical conditions, are related to the 
binding of phenobarbital by HSA. In the opinion of this author, 
alterations in these para.meters which ca.use changes in phenobarbital 
binding can contribute to drug dose-response variations. 
39. 
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CHAPTER V 
APPENDIX 
Phenobarbital Detennination: Method of Goldbaum (1952) 
This procedure has its basis in the fact that barbiturates have 
one absorption band in strong alkali and another in solutions between 10.2 
a:nC: 10.6 showing characteristics of two different resonance forms. The 
optical density difference between the two forms is greatest at 260 mu 
"for alkaline solutions containing 2-30 mcg. of barbiturates/ml." These 
differences follow Beers Law and are used to quantitiatively measure 
pb~nobarbital concentrations. From a survey of the literature, it is 
concluded that ultraviolet, spectrophotometric techniques are the most 
sensitive for quantitative and qualitative identification of barbiturates • 
.. 
The Goldbaum method provides a highly specific identification for barbi-
turates. It also allows for differentiation between many of the barbi• 
turates. 
Reagents: Borate buffer, 0.36 N sodium hydroxide, washed 
chloroform, glass distilled water, and the 
appropriate M/15 Sorensen's pH buffer. 
Decant solutions from dialysis bag and tube into separate test 
tubes. Pipette a portion of each solution into separate volumetric flasks 
and dilute to a concentration approximating 50 mcg./ml. Place 5 ml. of 
each diluted solution into separate, dry, 125 ml. polypropylene-stoppered 
separatory funnels. Acidify each solution with 3 drops of 6 N HCl. The 
pH should be between 1-2 using pH paper. 
Add 15 ml. of chloroform to each funnel and shake vigorously 
for 1 minute. Drain the chloroform layer through a #1 Whatman filter paper 
40. 
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containing approximately 10 gms. of Na2so4 into a dry separator:y funnel. 
Repeat the extraction with aliquots of 15, 10 and 10 ml. of chlorofom • 
.. 
Collect the filtered extracts in the second separator:y tunnei. Finally', 
rinse the filter with 10 ml. of chloroform. 
Pipette 10 ml. of 0.36 N NaOH into the separator:y funnel con-
taining the chloroform extracts and shake for 10 min. on a mechanical 
shaker to extract the phenobarbi ta.J. into the NaOH layer. After shaking, 
drain and discard the chloroform layer and collect the aqueous alkaline 
layer in a 12 ml. centrifuge tube. Centrifuge for 2-3 min. at 2000 rpm 
to precipitate any chloroform. 
Transfer approximately 3 ml. of the alkaline extract to matched 
quartz cuvette and determine the optical density at 260 mu. in a Beckman 
DU spectrophotometer against a water blank. Pipette 4 ml. of the alkaline 
extract into a tube containing 2 ml. of the Borate buffer. Pour 3 ml. •. of 
this solution into a clean cuvette and determine the optical density at 
260 mu. 
The appropriate Sorensen's buffer is carried through the same 
procedure as a reagent blank. 
The optical density of the alkaline-borate solution is corrected 
for dilution by multiplying by 1.5, and then it is subtracted from the 
optical density of the alkaline extract. The difference is employed to 
determine the phenobarbital concentration after appropriate dilution 
corrections. 
A standard curve is plotted of the optical density differences 
obtained from s~veral known concentrations of phenobarbital Na extracted 
using the above procedure. The experimental phenobarbital concentrations 
were determined from the standard. curve. 
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Protein Determination 
The method described by Gornall et al (1948) is based on the 
formation of a violet color ~hen copper sulfate in a strongly alkaline 
solution reacts with proteins or polypeptides having peptide or amide 
linkages. 
Reagents: Biuret reagent of GornaJ.l et al contains l.5 gm. 
cupric sulfate (CuS04.5H20), 6.o gm. potassium tartrate (NaKC4H4o6 .4~0) 
dissolved in approximately 500 ml. of distilled water to which is added 
300 ml. of 10% naOH. qs. to 1 liter. 
The dialysate, the HSA solutions, and the appropriate Sorensen's 
Buffer (reagent blank) are diluted 1:10 with water and one ml. of each is 
pipetted into separate test tubes. 4 ml. of the reagent is pipetted into 
each tube and the mixture allowed to stand for 30 minutes at room tempera-
ture. The optical densities of the solutions were determined in a Beckman 
DU with one cm. cells at 540 mu using a blank of glass distilled water. 
Human serum albumin standards were used as controls and various 
concentrations were employed to plot standard curves from which protein 
concentrations were determined. 
Partition Coefficient (Pc) and Per Cent Theoretical Extraction 
The Pc of phenobarbital Na and its extraction was determined 
using the method described by,Martin, (1962). 
The Pc is based upon the distribution of a solute between immis-
cible solvents. When a substance is added to the immiscible solvents in 
a quantity insufficient to saturate the solutions, it becomes distributed 
between the two solvents in a definite ratio. If c1 and c2 are the equi-
librium concentrations of the substance in solvent 1 and solvent 2, then 
the equilibri~ constant (k) = 
Pc = concentration of Phenobarbital 
concentration of Phenobarbital 
in Sorensen's Buffer (C1) 
in CHCl3 (c2) 
Once the Pc is determined, it is employed in the following formulas to 
calculate the theoretical extraction and percent recovery. 
, 
2. x mg./cc. theoretically extracted "" wl + w2 
Percent theoretical recovery = X ~ 
concentration in original solvent x lOO~ 
Where W = theoretical number of milligrams of solute extracted repeatedly 
from v1 ml. of one solvent (Sorensen's buffer) with successive portions of 
v2 ml. of a second immiscible solvent (CHc13), w1 "" amount of solute left 
in original solvent after the first extraction, and w2 = the amount of 
solvent remaining in the original solvent after repeating the extraction 
procedure using v2 number of ml. of solvent. 
The Pc procedure was as follows: 
l. Dilute 500 mg. of phenobarbital Na to 100 ml. with Sorensen's pH 7. 4 
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buf'fer ( c1 ) • Pipette 20 ml. of this solution into a separatory funnel and 
add 20 ml. washed CHC13 (pipette). Add 3 drops ot 6 N HCl and shake for 
1 minute. Pipette 10 ml. of"the CHC13 layer into a tared beaker. Evapor-
ate CHC13 to dryness and weigh beaker to determine the phenobarbital 
residue gravimetrically (c2). 
2. a) Dilute 500 mg. of phenobarbital Na to 100 ml. w1 th Sorensen's 
buf'fer. Pipette 40 ml. of this solution into a separatory funnel and 
add 40 ml. CHC13 (pipette). Add 3 drops of 6 N HCl and shake one minute. 
Remove 10 ml. CHc13 and repeat step #1, me.king the dilution correction. 
This serves as a control CHc13 extraction of phenobarbital and confirms 
step #l. 
b) Using a pipette, remove 20 ml. of the CHc13 layer remaining in 
the separatory funnel from (a) and place into a second separatory funnel. 
Pipette 20 ml. 0.36 N NaOH into the funnel. Shake the contents on a 
mechanical shaker tor 10 minutes. Pipette 10 ml. of the CHc13 layer into 
a tared beaker and repeat (a). 
c) Subtract (b) from (a) to determine the amount of phenobarbital 
extracted by NaOH from CHc13• 
The partition coefficient for 
Concentration of Phenobarbital in Sorensen's Buf'fer 
Concentration of Phenobarbital in CHC13 
was calculated to be l.226. 
Estimation of Protein Binding Sites - Method of Karush (1950) 
The mathematical analysis of binding data has been thorougbl.y 
discussed by Scatchard. (1949), Scatchard et al (1950), Karush and 
Sonenberg (1949)~ Karush (1950), Eichman et al (1962), and Keen (1966). 
These investigators estimated the number of binding sites per molecule 
of albumin for various drugs as follows: 
1. The moles of drug bound per mole of albumin (r) is deter-
mined for several concentrations of the drug. 
2. Then (r) is related to the molar concentration of the free 
drug present (c) by preparing a linear plot of r/c vs. r values. 
3. The curve resulting from the r/c vs. r relationship is 
extrapolated to the ordinate and the abscissa. The authors state that 
the values at the intercept points on the ordinate and abscissa equal nK 
and n respectively. "K" is equal to the association constant and "n" 
equals the number of binding sites. 
According to these authors, a plot of the r/c vs. r values 
produces a straight line when a single, homogeneous group of sites is 
responsible for drug binding. Scatchard. points out that the relationship 
between the concentrations of bound and free drug is expressed by the 
formula: 
r/c = nK - nr 
Should the r/c versus r plot produce a curved line, the deviation from a 
straight line may be due to electrostatic interaction. Electrostatic 
interaction is attributed to the repulsion of approaching drug ions by 
those already bound. An electrostatic correction factor may be applied 
46. 
by plotting r/c (f) versus r, when f equals e2w(Zp+r). "e" is the natural 
log, "w" the Debye-Huckle parameter, and Zp is the net charge on the pro-
" tein. The relationship between the concentrations of bound and free drugs 
are represented by the formula (Keen, 1966): 
r/c (f) = nK - rK 
If a curved plot persists a~er r/c correction for electro-
static interaction, heterogeneity of binding sites is assumed. The experi-
mental plot is extrapolated to graphically estimate the total number of 
binding sites, the number of binding site groups, and their affinity for 
the agent being studied. "Assuming that there are n binding sites.of two 
types, n and n2 with association constants K1 and !<21 and A is the limiting 
value of r/c as c approaches zero", the equation for the relationship 
between free and bound drug concentrations is: 
n1 IS_ n2 ~ 
r/c = + __ _ 
l + IS_ c 1 + K2c 
where n = n1 + ~, and line r/ c = n1 K1 + ~ = A (Karush, 1950; Goldbaum 
and Smith, 1954). The association constant (K) for each class of sites 
is determined by dividing the class nK value by its n value. 
The graphically determined n and K values are substituted into 
the appropriate equation to solve for r/c. The calculated r/c ratio vs. 
r values are plotted. This plot should produce a curve similar to that 
originally drawn and extrapolated (Keen, 1966) • 
The estimation of the number and character of phenobarbital 
binding sites per molecule of human serum albumin was determined in the 
manner described. 
CHAPTER VI 
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